[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.137.239. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
August 18, 2010

Minimizing Bias in Randomized TrialsThe Importance of Blinding

Author Affiliations

Author Affiliations: Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington and Center for Health Studies, Group Health, Seattle (Dr Psaty); and Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington (Dr Prentice).

JAMA. 2010;304(7):793-794. doi:10.1001/jama.2010.1161

In 1992, Hansson et al1 proposed a novel design, the prospective randomized open trial with blinded end-point assessments. The lack of blinding of investigators and patients simplified the conduct of the trial, which would become more similar to routine medical practice than the blinded design. The use of blinding for the adjudication of outcomes would preserve the benefits of a fully blinded trial. A number of trials have used this design to evaluate antihypertensive agents and more recently antidiabetic agents.24 These trials were thought to produce valid and, perhaps, more generalizable results.

First Page Preview View Large
First page PDF preview
First page PDF preview
×